SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: CDC signage at its headquarters in Georg
CDC
Trump nominates new CDC director, appoints various leaders to embattled agency
Erica Schwartz, a former deputy surgeon general and member of the U.S. military, will take over from what has amounted to a rapid succession of CDC leaders over the past year.
April 16, 2026
 · 
2 min read
 · 
Heather McKenzie
3D render, Futuristic surreal floating circle mirror that reflected on calm pastel sea horizon background
FDA
Drug pricing watchdog calls for increased transparency into FDA’s accelerated approval decisions
Greater transparency in FDA decision-making was possibly the most common theme for stakeholders interviewed by the Institute for Clinical and Economic Review in a new report focused on strengthening the agency’s accelerated approval program.
April 16, 2026
 · 
4 min read
 · 
Heather McKenzie
FDA signage at its headquarters in Maryland
FDA
FDA mulls compounding for peptides previously flagged over safety risks
With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier safety concerns.
April 16, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Abstract eye background. Vision concept. 3D Rendering
Gene therapy
MeiraGTx, spying hope in a failed trial, buys back eye disease gene therapy from J&J
J&J will hand over the rights to bota-vec for $25 million upfront, clearing MeiraGTx to seek regulatory approvals in the U.S. and EU in 2027.
April 16, 2026
 · 
2 min read
 · 
Annalee Armstrong
A plus grade in the notebook
diabetes
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the indication.
April 16, 2026
 · 
2 min read
 · 
Gabrielle Masson
A conceptual story about finance in the Eurozone, featuring €10, €20, and €50 notes in a supermarket shopping cart, with €100 notes in the background.
Insights
Can Europe turn world-class science into world-class scale?
Despite exceptional regional hubs and research strength, investors say Europe still needs more integrated incubators, smarter regulation and broader pools of patient capital to keep breakthrough companies growing at home.
April 16, 2026
 · 
5 min read
 · 
Jennifer C. Smith-Parker
Stacks of coins and a rocket flying above them as a metaphor for income growth.
Deals
Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026—already eclipsing last year’s total of $20.3 billion, according to a new J.P. Morgan report.
April 16, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration showing scales with bags of money tipped to side with most money
Funding
Revolution doubles stock offering target to $2B following pancreatic cancer win
After Revolution Medicines’ drug candidate doubled survival in a Phase 3 pancreatic cancer study, the biotech is hoping to attract more investor money, with new plans for a $2 billion stock and debt offering.
April 16, 2026
 · 
1 min read
 · 
Tristan Manalac
Novartis CEO Vas Narasimhan/Courtesy of Novartis
Artificial intelligence
Novartis CEO joins Anthropic board, embedding AI in the heart of biopharma
In recent months, Anthropic has been building more and more ties with the biopharma industry, including partnerships with Big Pharma companies such as Sanofi, Novo Nordisk and AbbVie.
April 16, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS